The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-06-24
DOI
10.1038/s41591-023-02427-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PEGOZAFERMIN PROVIDES BENEFICIAL LIPID EFFECTS IN SUBJECTS WITH SEVERE HYPERTRIGLYCERIDEMIA REGARDLESS OF BACKGROUND LIPID MODIFYING THERAPY STATUS: AN ANALYSIS OF THE PHASE 2 ENTRIGUE STUDY
- (2023) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial
- (2023) Robert S. Rosenson et al. NATURE MEDICINE
- FGF21 Reduces Lipid Accumulation in Bovine Hepatocytes by Enhancing Lipid Oxidation and Reducing Lipogenesis via AMPK Signaling
- (2022) Yezi Kong et al. Animals
- Pegozafermin led to significant metabolic benefits, in addition to robust beneficial effects on the liver, in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH)
- (2022) Naim Alkhouri et al. JOURNAL OF HEPATOLOGY
- Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations
- (2022) Marja-Riitta Taskinen et al. JCI Insight
- Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
- (2022) Aruna Das Pradhan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis
- (2021) Cong Liu et al. CARDIOVASCULAR RESEARCH
- 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia
- (2021) Salim S. Virani et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
- (2021) Stephen A. Harrison et al. NATURE MEDICINE
- Coronary Heart Disease Risk Associated with Primary Isolated Hypertriglyceridemia; a Population‐Based Study
- (2021) Seyedmohammad Saadatagah et al. Journal of the American Heart Association
- Advances in Biological Functions and Clinical Studies of FGF21
- (2021) Wei Lin et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
- (2020) Erik J. Tillman et al. Frontiers in Endocrinology
- MRI‐Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis
- (2020) Rohit Loomba HEPATOLOGY
- Fibroblast Growth Factor 21 and Browning of White Adipose Tissue
- (2019) Daniel Cuevas-Ramos et al. Frontiers in Physiology
- A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21
- (2019) Steven A. Kliewer et al. Cell Metabolism
- Increased Cardiovascular Risk in Hypertriglyceridemic Patients with Statin-Controlled LDL Cholesterol
- (2018) Gregory A Nichols et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
- (2018) Om P. Ganda et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Increased Residual Cardiovascular Risk in Patients with Diabetes and High vs. Normal Triglycerides Despite Statin-Controlled LDL Cholesterol
- (2018) Gregory A. Nichols et al. DIABETES OBESITY & METABOLISM
- High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk
- (2018) Peter P. Toth et al. Journal of the American Heart Association
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
- (2018) Edgar D. Charles et al. Obesity
- Understanding the Physiology of FGF21
- (2016) Ffolliott Martin Fisher et al. Annual Review of Physiology
- A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
- (2016) Saswata Talukdar et al. Cell Metabolism
- Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease
- (2016) Robert Klempfner et al.
- Severe hypertriglyceridemia and factors associated with acute pancreatitis in an integrated health care system
- (2016) Nazia Rashid et al. Journal of Clinical Lipidology
- The FGF21–adiponectin axis in controlling energy and vascular homeostasis
- (2016) Xiaoyan Hui et al. Journal of Molecular Cell Biology
- Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease
- (2016) Robert Klempfner et al. Circulation-Cardiovascular Quality and Outcomes
- Influence of Fatty Liver on the Severity and Clinical Outcome in Acute Pancreatitis
- (2015) Chunfang Xu et al. PLoS One
- Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels
- (2014) Peter P. Toth et al. ATHEROSCLEROSIS
- Triglycerides on the rise: should we swap seats on the seesaw?
- (2014) Peter Libby EUROPEAN HEART JOURNAL
- Current knowledge of hypertriglyceridemic pancreatitis
- (2014) Pedro Valdivielso et al. European Journal of Internal Medicine
- Residual Dyslipidemia Among United States Adults Treated With Lipid Modifying Therapy (Data from National Health and Nutrition Examination Survey 2009-2010)
- (2013) Nathan D. Wong et al. AMERICAN JOURNAL OF CARDIOLOGY
- Determining Triglyceride Reductions Needed for Clinical Impact in Severe Hypertriglyceridemia
- (2013) Jennifer B. Christian et al. AMERICAN JOURNAL OF MEDICINE
- The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
- (2013) Gregory Gaich et al. Cell Metabolism
- Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects
- (2009) Seiko Otokozawa et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Dyslipidaemic Pancreatitis Clinical Assessment and Analysis of Disease Severity and Outcomes
- (2009) F. Anderson et al. PANCREATOLOGY
- Acute pancreatitis: Etiology and common pathogenesis
- (2009) Guo-Jun Wang et al. WORLD JOURNAL OF GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation